- FDA's acting director of cell and gene therapies to leave positionVijay Kumar is leaving his role as acting director of CBER's Office of Therapeutic Products and will soon consider options both inside and outside the FDA, he told Endpoints News on Tuesday. Kuma…Endpoints · 24d ago↗ source
- Sarepta's FDA decision date; Flare gets Anna Protopapas as CEOPlus news about Deerfield, InflaRx, Praxis, Nuvectis, Pyxis Oncology, Vistagen, Arcutis Biotherapeutics and Nxera. 🔎 FDA to decide on future of Sarepta exon-skipping drugs by end of February: Th…Endpoints · 24d ago↗ source
- Nominations are open for the 2026 Endpoints 11 awardsThere’s never been a higher bar for innovation than right now. Almost any promising molecule quickly has a horde of copycats. Development costs keep rising. Investors are leaning on seemingly saf…